In June 2021, the agency approved Wegovy (semaglutide 2.4 mg once weekly) for weight management in adults with a body mass index (BMI) of 30 kg/m or greater (obesity), or a BMI of 27 kg/m or greater (overweight) with at least one weight-related comorbidity such as hypertension, dyslipidemia, or obstructive sleep apnea
Even among other doctors, I still frequently hear, If only the patient would eat less or exercise more. Of course, this outdated thinking is not the case at all, Dr
According to the World Health Organization, GLP compliance is typically limited to Stage 2 of the drug development process
Scherz-Shouval et al
Research design & analyst oversight At GMI, our research methodology is built on a foundation of human expertise, rigorous validation, and complete transparency
What Happens After Stopping GLP-1s A study found that one year after stopping semaglutide (the active ingredient in Ozempic), patients regained two-thirds of their prior weight loss over the following 52 weeks
